Skip to main content

Advertisement

SpringerLink
Log in

VEGFR, RET, and RAF/MEK/ERK Pathway Take Part in the Inhibition of Osteosarcoma MG63 Cells with Sorafenib Treatment

  • Original Paper
  • Published:
Cell Biochemistry and Biophysics Aims and scope Submit manuscript

Abstract

Osteosarcoma (OS) is the leading primary malignant bone tumor in children and young adults. It is response for a high mortality rate. Nowadays, few researches have been performed on sorafenib against OS and no tools are available to guide the use of sorafenib in the OS treatment. In this study, we aim to investigate the effect of sorafenib on OS cell MG63 and figure the potential effective molecular pathway of its function. In the present study, we performed assays of cell proliferation, RT-PCR, and western blot to investigate the effect of sorafenib on OS MG63 cells and to elucidate the molecular actions of sorafenib against RTKs VEGFR2 and RET, as well as MEK/ERK signaling pathway. The present study confirmed that sorafenib could inhibit the proliferation of OS MG63 cells and caused a series of biomolecule effects, including the change of VEGFR2 and ERK gene expression, and the phosphorylation alteration of VEGFR2, RET, and MEK1 proteins. VEGFR2, RET, and MEK/ERK signaling pathway are involved in the pharmacological mechanism of sorafenib. They are potential candidate targets for OS treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Ferrari, S., Smeland, S., Mercuri, M., Bertoni, F., Longhi, A., Ruggieri, P., et al. (2005). Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: A joint study by the Italian and Scandinavian Sarcoma Groups [Clinical Trial Comparative Study Multicenter Study]. Journal of Clinical Oncology, 23(34), 8845–8852.

    Article  PubMed  Google Scholar 

  2. Ozaki, T., Flege, S., Kevric, M., Lindner, N., Maas, R., Delling, G., et al. (2003). Osteosarcoma of the pelvis: experience of the Cooperative Osteosarcoma Study Group [Multicenter Study Research Support, Non-U.S. Gov’t]. Journal of Clinical Oncology, 21(2), 334–341.

    Article  PubMed  Google Scholar 

  3. Smithey, B. E., Pappo, A. S., & Hill, D. A. (2002). C-kit expression in pediatric solid tumors: a comparative immunohistochemical study [Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, P.H.S.]. The American Journal of Surgical Pathology, 26(4), 486–492.

    Article  PubMed  Google Scholar 

  4. McGary, E. C., Weber, K., Mills, L., Doucet, M., Lewis, V., Lev, D. C., et al. (2002). Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571 [Research Support, U.S. Gov’t, P.H.S.]. Clinical Cancer Research, 8(11), 3584–3591.

    CAS  PubMed  Google Scholar 

  5. Kaya, M., Wada, T., Akatsuka, T., Kawaguchi, S., Nagoya, S., Shindoh, M., et al. (2000). Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clinical Cancer Research, 6(2), 572–577.

    CAS  PubMed  Google Scholar 

  6. Lyons, J. F., Wilhelm, S., Hibner, B., & Bollag, G. (2001). Discovery of a novel Raf kinase inhibitor [Review]. Endocrine-Related Cancer, 8(3), 219–225.

    Article  CAS  PubMed  Google Scholar 

  7. Sridhar, S. S., Hedley, D., & Siu, L. L. (2005). Raf kinase as a target for anticancer therapeutics. Molecular Cancer Therapeutics, 4(4), 677–685.

    Article  CAS  PubMed  Google Scholar 

  8. Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., et al. (2004). BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Research, 64(19), 7099–7109.

    Article  CAS  PubMed  Google Scholar 

  9. Mitsudomi, T. (2010). Advances in target therapy for lung cancer. Japanese Journal of Clinical Oncology, 40(2), 101–106.

    Article  PubMed  Google Scholar 

  10. Merseburger, A. S., Simon, A., Waalkes, S., & Kuczyk, M. A. (2009). Sorafenib reveals efficacy in sequential treatment of metastatic renal cell cancer [Review]. Expert Review of Anticancer Therapy, 9(10), 1429–1434.

    Article  CAS  PubMed  Google Scholar 

  11. Min, L., He, B., & Hui, L. (2011). Mitogen-activated protein kinases in hepatocellular carcinoma development. Seminars in Cancer Biology, 21(1), 10–20.

    Article  CAS  PubMed  Google Scholar 

  12. Mao, W. F., Shao, M. H., Gao, P. T., Ma, J., Li, H. J., Li, G. L., et al. (2012). The important roles of RET, VEGFR2 and the RAF/MEK/ERK pathway in cancer treatment with sorafenib. Acta Pharmacologica Sinica, 33(10), 1311–1318.

    Article  CAS  PubMed  Google Scholar 

  13. Molina, M. A., Codony-Servat, J., Albanell, J., Rojo, F., Arribas, J., & Baselga, J. (2001). Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells [Research Support, Non-U.S. Gov’t]. Cancer Research, 61(12), 4744–4749.

    CAS  PubMed  Google Scholar 

  14. Heinrich, M. C., Corless, C. L., Demetri, G. D., Blanke, C. D., von Mehren, M., Joensuu, H., et al. (2003). Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor [Clinical Trial Clinical Trial, Phase II Comparative Study Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, Non-P.H.S.]. Journal of Clinical Oncology, 21(23), 4342–4349.

    Article  CAS  PubMed  Google Scholar 

  15. Heinrich, M. C., Maki, R. G., Corless, C. L., Antonescu, C. R., Harlow, A., Griffith, D., et al. (2008). Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor [Clinical Trial, Phase I Clinical Trial, Phase II Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, Non-P.H.S.]. Journal of Clinical Oncology, 26(33), 5352–5359.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  16. Feld, R., Sridhar, S. S., Shepherd, F. A., Mackay, J. A., & Evans, W. K. (2006). Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: A systematic review. Journal of Thoracic Oncology, 1(4), 367–376.

    Article  PubMed  Google Scholar 

  17. Wolfesberger, B., Tonar, Z., Gerner, W., Skalicky, M., Heiduschka, G., Egerbacher, M., et al. (2010). The tyrosine kinase inhibitor sorafenib decreases cell number and induces apoptosis in a canine osteosarcoma cell line. Research in Veterinary Science, 88(1), 94–100.

    Article  CAS  PubMed  Google Scholar 

  18. Yang, S. Y., Yu, H., Krygier, J. E., Wooley, P. H., & Mott, M. P. (2007). High VEGF with rapid growth and early metastasis in a mouse osteosarcoma model. Sarcoma,. doi:10.1155/2007/95628.

    PubMed Central  PubMed  Google Scholar 

  19. Cuccuru, G., Lanzi, C., Cassinelli, G., Pratesi, G., Tortoreto, M., Petrangolini, G., et al. (2004). Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma [Research Support, Non-U.S. Gov’t]. Journal of the National Cancer Institute, 96(13), 1006–1014.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

Institution of all of the authors has received funding from the National Natural Science Foundation of China (Grant No. 30471760). In addition, we gratefully acknowledge the assistance of Gailing Li in Shanghai Chest Hospital. They gave us some proposals in point.

Author information

Authors and Affiliations

  1. Department of Orthopedics, Tongji Hospital of Tongji University, Shanghai, 200065, China

    Jiong Mei, Xiaozhong Zhu, Zhiyuan Wang & Zheren Wang

Authors
  1. Jiong Mei
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiaozhong Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhiyuan Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zheren Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jiong Mei.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mei, J., Zhu, X., Wang, Z. et al. VEGFR, RET, and RAF/MEK/ERK Pathway Take Part in the Inhibition of Osteosarcoma MG63 Cells with Sorafenib Treatment. Cell Biochem Biophys 69, 151–156 (2014). https://doi.org/10.1007/s12013-013-9781-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12013-013-9781-7

Keywords

Search

Navigation